Document is current
Any future updates will be listed below
-
Authors
Schramm, Zachery A.
Leroux, Brian G.
Radick, Andrea C.
Ventura, Alicia S.
Klein, Jared W.
Samet, Jeffrey H.
Saxon, Andrew J.
Kim, Theresa W.
Tsui, Judith I. http://orcid.org/0000-0003-0877-5399
-
Funding
Funding for this research was provided by:
National Institute on Drug Abuse (R44DA044053)
-
License Information
Text and Data Mining valid from 2020-07-31
Version of Record valid from 2020-07-31
-
More Information
Article History
Received: 14 February 2020
Accepted: 21 July 2020
First Online: 31 July 2020
Ethics approval and consent to participate
: The TAAB study received approval from the University of Washington’s Institutional Review Board (IRB) in Seattle, Washington (IRB00005069) and from Boston University School of Medicine Institutional Review Board in Boston, Massachusetts (H-37779). The study follows adverse events reporting procedures required by the National Institute on Drug Abuse (NIDA) and each institution’s IRB. This study is registered at ClinicalTrials.gov (NCT03779997).
: Not applicable.
: Andrew Saxon receives compensation as an advisor to Alkermes, Inc. and also receives travel support from Alkermes, Inc. The remaining authors declare that they have no competing interests. Specifically, none of the authors are employees of emocha Mobile Health, Inc. nor received in-kind donations or funding that was not through NIDA.
